Wellness Center USA (WCUI) 10-Q 30 Sep 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Jun. 30, 2019shares
Document And Entity Information
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	0001516887
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	107,497,077
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Current Assets
Cash	$ 49,603	$ 4,210
Inventories	55,000
Prepaid expenses and other current assets		1,550
Total Current Assets	104,603	5,760
Property and equipment, net	1,827	2,619
Other assets	1,760	16,760
Total Other Assets	3,587	19,379
TOTAL ASSETS	108,190	25,139
Current Liabilities
Accounts payable and accrued expenses	736,246	572,753
Deferred revenue		8,624
Convertible notes payable		202,922
Loans payable from officers and shareholders	374,250	66,000
Total Current Liabilities	1,110,496	850,299
Shareholders' Deficit
Common stock, par value $0.001, 185,000,000 shares authorized; 107,497,077 and 100,952,569 shares issued and outstanding, respectively	107,497	100,952
Additional paid-in capital	23,716,791	22,450,252
Accumulated deficit	(25,045,034)	(22,974,740)
Total Wellness Center USA shareholders' deficit	(1,220,746)	(423,536)
Non-controlling interest	218,440	(401,624)
Total Shareholder's deficit	(1,002,306)	(825,160)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 108,190	$ 25,139

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	185,000,000	185,000,000
Common stock, shares, issued	107,497,077	100,952,569
Common stock, shares, outstanding	107,497,077	100,952,569

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Sales:
Total Sales	$ 7,625	$ 71,500	$ 33,375	$ 139,250
Cost of goods sold	4,575	16,967	20,025	51,625
Gross profit	3,050	54,533	13,350	87,625
Operating expenses	404,210	837,368	1,415,667	1,732,848
Loss from operations	(401,160)	(782,835)	(1,402,317)	(1,645,223)
Other expenses
Amortization of debt discount		(69,837)	(72,078)	(205,674)
Financing costs	(108,630)	(720,517)	(182,064)	(790,939)
Loss on modification of conversion price on convertible note payable				(158,400)
Loss on modification of exercise price on warrants in connection with convertible note payable				(5,445)
Interest expense	(6,042)	(7,248)	(17,771)	(20,336)
Total other expenses	(114,672)	(797,602)	(271,913)	(1,180,794)
NET LOSS	(515,832)	(1,580,437)	(1,674,230)	(2,826,017)
Net loss (gain) attributable to non-controlling interest	4,917	(2,179)	9,319	65,263
Loss from deconsolidation of non-controlling interest			(405,383)
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	(510,915)	(1,582,616)	(2,070,294)	(2,760,754)
Deemed dividend relating to settlement with shareholder		(433,000)		(433,000)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (510,915)	$ (2,015,616)	$ (2,070,294)	$ (3,193,754)
BASIC AND DILUTED LOSS PER SHARE	$ 0	$ (0.02)	$ (0.02)	$ (0.03)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	107,433,349.4	95,906,597	106,575,313	92,912,125
Trade [Member]
Sales:
Total Sales	$ 3,108	$ 60,500	$ 19,508	$ 96,500
Consulting Services [Member]
Sales:
Total Sales	$ 4,517	$ 11,000	$ 13,867	$ 42,750

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2017	$ 90,285	$ 19,069,211	$ (19,132,557)	$ 26,939	$ (317,388)	$ (290,449)
Balance, shares at Sep. 30, 2017	90,284,916
Common shares issued for cash	$ 333	49,667		50,000		50,000
Common shares issued for cash, shares	333,333
Exercise of stock warrants	$ 1,407	169,507		170,914		170,914
Exercise of stock warrants, shares	1,407,619
Fair value of common stock issued for services	$ 770	110,530		111,300		111,300
Fair value of common stock issued for services, shares	770,000
Shares issued upon conversion of note payable and accrued interest	$ 1,746	172,817		174,563		174,563
Shares issued upon conversion of note payable and accrued interest, shares	1,745,631
Shares issued upon conversion of loans payable from officers and shareholders	$ 3,019	403,981		407,000		407,000
Shares issued upon conversion of loans payable from officers and shareholders, shares	3,019,165
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		30,583		30,583		30,583
Fair value of warrants issued as an inducement for conversion of loans payable from officers and shareholders		689,934		689,934		689,934
Fair value of vested stock options		486,642		486,642		486,642
Fair value of common stock issued in connection with convertible note payable	$ 487	69,935		70,422		70,422
Fair value of common stock issued in connection with convertible note payable, shares	486,849
Fair value of shares and warrants issued upon settlement of Favored Nations clause	$ 1,067	431,933	(433,000)
Fair value of shares and warrants issued upon settlement of Favored Nations clause, shares	1,066,667
Discount on convertible note payable due to beneficial conversion and warrants		150,000		150,000		150,000
Loss on modification of conversion price and exercise price on warrants in connection with convertible note payable		163,845		163,845		163,845
Fair value of additional shares issued upon conversions of note payable
Termination of non-controlling interest agreement
Contribution of capital by joint venture partner
Net loss			(2,760,754)	(2,760,754)	(65,263)	(2,826,017)
Balance at Jun. 30, 2018	$ 99,114	21,998,585	(22,326,311)	(228,612)	(382,651)	(611,263)
Balance, shares at Jun. 30, 2018	99,114,180
Balance at Mar. 31, 2018	$ 92,879	19,841,396	(20,310,695)	(376,420)	(384,830)	(761,250)
Balance, shares at Mar. 31, 2018	92,879,384
Common shares issued for cash	$ 333	49,667		50,000		50,000
Common shares issued for cash, shares	333,333
Fair value of common stock issued for services	$ 620	83,980		84,600		84,600
Fair value of common stock issued for services, shares	620,000
Shares issued upon conversion of note payable and accrued interest	$ 1,196	118,367		119,563		119,563
Shares issued upon conversion of note payable and accrued interest, shares	1,195,631
Shares issued upon conversion of loans payable from officers and shareholders	$ 3,019	403,981		407,000		407,000
Shares issued upon conversion of loans payable from officers and shareholders, shares	3,019,165
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		30,583		30,583		30,583
Fair value of warrants issued as an inducement for conversion of loans payable from officers and shareholders		689,934		689,934		689,934
Fair value of vested stock options		348,744		348,744		348,744
Fair value of shares and warrants issued upon settlement of Favored Nations clause	$ 1,067	431,933	(433,000)
Fair value of shares and warrants issued upon settlement of Favored Nations clause, shares	1,066,667
Termination of non-controlling interest agreement
Net loss			(1,582,616)	(1,582,616)	2,179	(1,580,437)
Balance at Jun. 30, 2018	$ 99,114	21,998,585	(22,326,311)	(228,612)	(382,651)	(611,263)
Balance, shares at Jun. 30, 2018	99,114,180
Balance at Sep. 30, 2018	$ 100,952	22,450,252	(22,974,740)	(423,536)	(401,624)	(825,160)
Balance, shares at Sep. 30, 2018	100,952,569
Common shares issued for cash	$ 143	9,857		10,000		$ 10,000
Common shares issued for cash, shares	142,857					142,857
Exercise of stock warrants, shares
Fair value of common stock issued for services	$ 1,277	77,752		79,029		$ 79,029
Fair value of common stock issued for services, shares	1,277,143					1,277,143
Shares issued upon conversion of note payable and accrued interest	$ 4,811	285,361		290,172		$ 290,172
Shares issued upon conversion of note payable and accrued interest, shares	4,810,222
Fair value of vested stock options		235,819		235,819		235,819
Fair value of common stock issued in connection with convertible note payable	$ 314	21,686		22,000		22,000
Fair value of common stock issued in connection with convertible note payable, shares	314,286
Fair value of additional shares issued upon conversions of note payable		160,064		160,064		160,064
Termination of non-controlling interest agreement			(405,383)	(405,383)	405,383	(405,383)
Contribution of capital by joint venture partner		476,000		476,000	224,000	700,000
Net loss			(1,664,911)	(1,664,911)	(9,319)	(1,674,230)
Balance at Jun. 30, 2019	$ 107,497	23,716,791	(25,045,034)	(1,220,746)	218,440	(1,002,306)
Balance, shares at Jun. 30, 2019	107,497,077
Balance at Mar. 31, 2019	$ 104,012	23,200,187	(24,534,119)	(1,229,920)	151,357	(1,078,563)
Balance, shares at Mar. 31, 2019	104,012,153
Fair value of common stock issued for services	$ 1,157	68,272		69,429		69,429
Fair value of common stock issued for services, shares	1,157,143
Shares issued upon conversion of note payable and accrued interest	$ 2,328	114,061		116,389		116,389
Shares issued upon conversion of note payable and accrued interest, shares	2,327,781
Fair value of vested stock options		72,641		72,641		72,641
Fair value of additional shares issued upon conversions of note payable		108,630		108,630		108,630
Termination of non-controlling interest agreement
Contribution of capital by joint venture partner		153,000		153,000	72,000	225,000
Net loss			(510,915)	(510,915)	(4,917)	(515,832)
Balance at Jun. 30, 2019	$ 107,497	$ 23,716,791	$ (25,045,034)	$ (1,220,746)	$ 218,440	$ (1,002,306)
Balance, shares at Jun. 30, 2019	107,497,077

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities
Net loss	$ (1,674,230)	$ (2,826,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	792	2,243
Amortization of debt discount	72,078	205,674
Fair value of common shares issued for services	79,029	111,300
Fair value of stock options issued for services	235,819	486,642
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		30,583
Fair value of warrants issued upon conversion of loans payable from officers and shareholders		689,934
Fair value of additional shares issued upon conversions of note payable	160,064
Fair value of common stock issued with convertible note payable	22,000
Loss on abandonment of lease	65,000
Loss on modification of conversion price on convertible note payable		158,400
Loss on modification of exercise price on warrants in connection with convertible note payable		5,445
Fair value of common stock issued in connection with convertible note payable		70,422
(Increase) Decrease in:
Accounts receivable		24,999
Inventories	(55,000)	321
Prepaid expenses and other assets	16,550	(2,111)
(Decrease) Increase in:
Accounts payable and accrued expenses	113,665	273,774
Accrued payroll - officers		(13,440)
Deferred revenue	(8,624)	(8,250)
Net cash used in operating activities	(972,857)	(790,081)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	333,250	427,500
Repayment of loans payable from officers and shareholders	(25,000)	(20,500)
Proceeds from convertible note payable		150,000
Common stock and warrants issued for cash	10,000	50,000
Exercise of stock warrants		170,914
Contribution of capital by joint venture partner	700,000
Net cash provided by financing activities	1,018,250	777,914
Net increase (decrease) in cash	45,393	(12,167)
Cash beginning of period	4,210	29,369
Cash end of period	49,603	17,202
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Conversion of convertible note payable and accrued interest into common shares	290,172	174,563
Debt discount on convertible note payable		$ 150,000

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION Organization and Operations Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI. Basis of Presentation of Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending September 30, 2019. Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the nine months ended June 30, 2019, the Company incurred a net loss of $1,674,230 and used cash in operations of $972,857, and had a shareholders’ deficit of $1,002,306 as of June 30, 2019. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2018 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. At June 30, 2019, the Company had cash on hand in the amount of $49,603. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the nine months ended June 30, 2019, the Company received $1,018,250 through short-term loans, contributions of capital by a joint venture partner and the sale of common stock. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 100 % StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015/November 15, 2018 50 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 50.5 % Through October 2018, PSI was operated by PDC, a joint venture between PSI and the Medical Alliance, Inc (“TMA”). On November 15, 2018, the Company and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. In December 2018, the Company and its wholly-owned subsidiary, Psoria-Shield, Inc. (“PSI”), entered into a Joint Venture Agreement with PSI Gen 2 Funding, Inc. (“GEN2”), an Illinois corporation, to further development, marketing, licensing and/or sale of PSI technology and products. The joint venture is conducted through NEO Phototherapy, LLC, a recently formed Illinois limited liability company (“NEO”), with principal offices and records to be maintained at WCUI’s offices. See Non-Controlling Interests in Note 2 for more details. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the nine months ended June 30, 2019 and 2018, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At June 30, 2019 and 2018, the dilutive impact of outstanding stock options of 15,687,738 and 17,890,000 shares, respectively, and outstanding warrants for 66,832,049 and 69,022,753 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive. Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at September 30, 2018 was $8,624. No deferred revenue was recorded at June 30, 2019. Non-controlling Interests Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the three months ended December 31, 2018, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO. PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. Repayment of the $700,000 investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative net income/distributable cash in the amount of $300,000. Distributions thereafter will be made to PSI, GEN2 and other members in proportion to their respective Unit ownership, at the times and in the manner determined from time to time by the managers, in their sole discretion. GEN2 consists of accredited investors, and investment participation from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. As of June 30, 2019, GEN2 had received $700,000 of investments to contribute to NEO and the Company recorded its proportionate share of $476,000 to additional paid-in-capital and $224,000 to non-controlling interest. During the three and nine months ended June 30, 2019, NEO recorded a loss of $15,367 and $17,373, respectively, relating to its operations. Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods. Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Loans Payable from Officers and

Loans Payable from Officers and Shareholders	9 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Loans Payable from Officers and Shareholders	NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS As of September 30, 2018, loans payable from officers and shareholders of $66,000 were outstanding. During the nine months ended June 30, 2019, the Company borrowed $333,250 from its officers and shareholders and repaid $25,000 to its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. As of June 30, 2019, loans payable to officers and shareholders of $374,250 were outstanding.

Convertible Note Agreements

Convertible Note Agreements	9 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Convertible Note Agreements	NOTE 4 – CONVERTIBLE NOTE AGREEMENTS June 30, 2018 September 30, 2018 Convertible note payable (a) $ - $ 165,000 Convertible note payable (b) - 110,000 Debt discount – unamortized balance - (72,078 ) Convertible note payable, net $ - $ 202,922 (a) On March 5, 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). The balance of the unamortized discount at September 30, 2018 was $3,837. During the nine months ended June 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the nine months ended June 30, 2019. During the nine months ended June 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company’s common stock. During the nine months ended June 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at June 30, 2019. No amounts were outstanding under the agreement as of June 30, 2019. (b) On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). As of September 30, 2018, the Company had amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. During the nine months ended June 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the three and nine months ended June 30, 2019. During the three and nine months ended June 30, 2019, the Company amortized $21,389 and $68,241 of debt discount, respectively, leaving no unamortized balance at June 30, 2019. On April 2, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company’s common stock. No amounts were outstanding under the agreement as of June 30, 2019.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Shareholders' Equity	NOTE 5 – SHAREHOLDERS’ EQUITY Common shares issued for cash During the nine months ended June 30, 2019, the Company received $10,000 from the sale of 142,857 shares of its common stock. In connection with the sale, the Company issued a warrant to the shareholder to purchase 284,714 shares of the Company’s common stock. The warrant expires five years from the date of grant and has an exercise price of $0.15 per share. Common shares issued for Services During the nine months ended June 30, 2019, the Company issued 1,277,143 shares of its common stock valued at $79,029 for services provided by consultants. The shares were valued at the trading price of the common stock at the date of issuance. Stock Options On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. During the nine months ended June 30, 2019, the Company granted options to an employee to purchase an aggregate total of 187,500 shares of its common stock with an aggregate fair value of $8,684. The options have exercise prices of $0.04 and $0.06 per share and expire five years from the date of grant. The shares vested equally each quarter beginning on December 31, 2018. The Company valued the options using a Black-Scholes option pricing model. The assumptions used for the option granted during the nine months ended June 30, 2019 are as follows: Exercise price $ 0.04 - $ 0.06 Expected dividends - Expected volatility 126.8 - 137.4% Risk free interest rate 1.73 - 2.47 Expected life of options 2.5 During the nine months ended June 30, 2019, the Company recorded $235,819 of stock compensation for the value of all outstanding options, and as of June 30, 2019, unvested compensation of $452,659 remained that will be amortized over the remaining vesting period. The table below summarizes the Company’s stock option activities for the nine months ended June 30, 2019: Number of Exercise Price Range Weighted Average Fair Value at Balance, September 30, 2018 17,946,667 $ 0.10 - 2.00 $ 0.28 $ 3,244,755 Granted 187,500 0.04 - 0.06 0.05 8,684 Cancelled (646,429 ) 0.14 - 0.19 0.17 - Exercised - - - - Expired (1,800,000 ) 0.40 0.40 - Balance, June 30, 2019 15,687,738 $ 0.04 – 2.00 $ 0.27 $ 3,253,439 Vested and exercisable, June 30, 2019 11,946,667 $ 0.04 – 2.00 $ 0.31 $ 2,185,052 Unvested, June 30, 2019 3,741,071 $ 0.14 – 0.19 $ 0.14 $ 1,068,387 There was no aggregate intrinsic value for option shares outstanding at June 30, 2019. As of June 30, 2019, there were 14,312,262 shares of stock options remaining available for issuance under the 2010 Plan. The following table summarizes information concerning outstanding and exercisable options as of June 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.06 - 0.39 13,975,238 3.30 $ 0.15 10,234,167 3.13 $ 0.15 0.40 - 0.99 312,500 0.62 0.40 312,500 0.62 0.40 1.00 - 1.99 750,000 1.50 1.00 750,000 1.50 1.00 2.00 650,000 1.50 2.00 650,000 1.50 2.00 $ 0.06 - 2.00 15,687,738 3.06 $ 0.27 11,946,667 3.07 $ 0.31 Stock Warrants During the nine months ended June 30, 2019, the Company issued a warrant to purchase 284,714 shares with an exercise price of $0.15 per share as part of the sale of equity units. The warrant expires five years from the date of grant. The table below summarizes the Company’s warrants activities for the nine months ended June 30, 2019: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Issuance Balance, September 30, 2018 67,907,728 $ 0.12 - 0.67 $ 0.17 $ 3,434,560 Granted 284,714 0.15 0.15 17,803 Cancelled - - - - Exercised - - - - Expired (1,360,393 ) 0.40 – 0.67 0.47 - Balance, June 30, 2019 66,832,049 $ 0.12 - 0.40 $ 0.17 $ 3,452,363 Vested and exercisable, June 30, 2019 66,832,049 $ 0.12 - 0.40 $ 0.17 $ 3,452,363 There was no aggregate intrinsic value for warrant shares outstanding at June 30, 2019. The following table summarizes information concerning outstanding and exercisable warrants as of June 30, 2019: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 59,279,384 2.15 $ 0.15 59,279,384 2.15 $ 0.15 0.21 – 0.49 7,552,665 1.05 0.26 7,552,665 1.05 0.26 0.50 – 0.67 - - - - - - $ 0.12 – 0.67 66,832,049 2.03 $ 0.17 66,832,049 2.03 $ 0.17

Segment Reporting

Segment Reporting	9 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Reporting	NOTE 6 – SEGMENT REPORTING Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company operates in the following business segments: (i) Medical Devices: (ii) Authentication and Encryption Products and Services: The detailed segment information of the Company is as follows: Assets By Segment June 30, 2019 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 1,687 $ 47,916 $ - $ 49,603 Inventories - 55,000 - 55,000 Total current assets 1,687 102,916 - 104,603 Property and equipment, net - - 1,827 1,827 Other assets - 1,760 - 1,760 Total other assets - 1,760 1,827 3,587 TOTAL ASSETS $ 1,687 $ 104,676 $ 1,827 $ 108,190 Operations by Segment For the Nine Months Ended June 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 716,900 399,111 299,656 1,415,667 Loss from operations $ (716,900 ) $ (399,111 ) $ (286,306 ) $ (1,402,317 ) For the Nine Months Ended June 30, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 45,000 $ 51,500 $ 96,500 Consulting services - - 42,750 42,750 Total Sales - 45,000 94,250 139,250 Cost of goods sold - - 51,625 51,625 Gross profit - 45,000 42,625 87,625 Operating expenses 940,169 176,859 615,820 1,732,848 Loss from operations $ (940,169 ) $ (131,859 ) $ (573,195 ) $ (1,645,223 )

Legal Matters

Legal Matters	9 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 7 – LEGAL MATTERS The Company is periodically engaged in legal proceedings arising from and relating to its business operations. We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations. However, we recently decided to attempt to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, we have negotiated settlement of all but $80,454 in ex-employee wage and benefits claims, with agreement to pay such remaining amount, together with interest at the rate of 4% per annum on the principal amount from time to time outstanding, when and as cash flow permits. In periodic reports on Forms 10K and 10Q for the periods ending September 30, 2017 and December 31, 2017, respectively, the Company disclosed that on May 25, 2017, the SEC’s Chicago Regional Office informed it that it had made a preliminary determination to recommend filing of an enforcement action against the Company and its CEO based on possible violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and Section 17(a) of the Securities Act, and Section 15(a) of the Exchange Act. Subsequent discussions resulted in the submission of an Offer of Settlement (“Settlement”) through an administrative cease and desist action on November 17, 2017, which was accepted by the SEC on April 12, 2018, as disclosed on Form 8K filed April 18, 2018. Pursuant to the Settlement, the Company neither admitted nor denied any of the allegations, but was enjoined from violating the above-referenced Sections and Rule. The Settlement imposed no financial penalties or sanctions against the Company. The Form 8K also disclosed that on April 13, 2018, the SEC filed a separate complaint against the CEO in the U.S. District Court for the Northern District of Illinois, asserting the allegations noted above, as well as allegations that he manipulated the price of company shares through undisclosed trading, realizing more than $130,000 from such trading. On the date of filing, the CEO voluntarily resigned as an officer and director of the Company. Without admitting or denying the allegations, the CEO consented to the entry of the judgment, which was entered on September 26, 2018 by the U.S. District Court for the Northern District of Illinois. The judgment permanently enjoined him from violating the anti-fraud provisions of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and the broker registration provisions of Section 15(a) of the Exchange Act. It also bars him from serving as an officer or director of a public company and from participating in penny stock offerings, and ordered disgorgement and interest and penalties to be determined by the court. On January 31, 2019, the employment agreement between the Company and its former CEO dated April 1, 2018 was terminated and his service thereunder as Director of Business Development ceased as of that date.

Commitments

Commitments	9 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 8 – COMMITMENTS The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000, or a total aggregate remaining payment of approximately $640,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. During the nine months ended June 30, 2019, the Company recorded an accrual for the estimated potential settlement and wrote-off its $15,000 security deposit relating to the lease.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 9 – SUBSEQUENT EVENTS Subsequent to June 30, 2019, the Company borrowed $50,000 from two of its officers and shareholders. The loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. On September 3, 2019, our Board of Directors unanimously approved, subject to stockholder approval: (1) execution and delivery of a proposed Share Exchange Agreement with DTI Holdings, Inc. (“DTI”) relating to the share exchange and transfer of certain assets of SCI pursuant to the terms and conditions of a Memorandum of Agreement in substantially the form of the copy presented to the Board (“Agreement”); and (2) the amendment of our Articles of Incorporation to increase our total authorized capital stock from 185,000,000 common shares to 200,000,000 common shares (“Amendment”). As of September 18, 2019, holders of a majority of the outstanding shares of voting capital stock have executed written stockholder consents approving these actions. The Agreement provides, among other things, that: (1) DTI will pay the Company $500,000 upon the execution of a definitive share exchange agreement (“Share Exchange Agreement”) which the parties will endeavor to negotiate and execute as quickly as possible, and not later than October 15, 2019; (2) DTI will pay the Company an additional $500,000 within seven days following the completion date of the transfer of all assets and/or full ownership of SCI to DTI, with such date to occur within 120 days following execution of the Share Exchange Agreement; (3) DTI will issue to the Company 3,112,000 shares of DTI common stock and will guaranty that the value of the 3,112,000 shares of DTI common stock will have a value of at least $4.50 per share ($14,004,000, in the aggregate), as of December 31, 2021; (4) To the extent that the value of the DTI common shares, as of December 31, 2021, is less than $4.50 per share ($14,004,000, in the aggregate), DTI will issue additional shares of DTI common stock, at the then current fair market value, in an amount sufficient to cause the resulting aggregate value of all shares of DTI common stock issued to the Company to be $14,004,000, in the aggregate; (5) DTI will assign the assets transferred by SCI, including trademarks, intellectual properties, and patents, to its subsidiary, Femtobitz, Inc., a Delaware corporation, and will pay to the Company 1% of annual gross revenue arising from or relating to operation of Femtobitz, Inc.; and (6) Upon closing of the share exchange, the Company’s Chairman will be appointed an advisory board member of DTI and a board member of Femtobitz, Inc. Discussions between the Company and DTI are in the initial stages and there can be no assurance that the proposed transaction described in the Agreement will be concluded successfully on the terms described or any alternate terms that may be proposed hereafter.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 100 % StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015/November 15, 2018 50 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 50.5 % Through October 2018, PSI was operated by PDC, a joint venture between PSI and the Medical Alliance, Inc (“TMA”). On November 15, 2018, the Company and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. In December 2018, the Company and its wholly-owned subsidiary, Psoria-Shield, Inc. (“PSI”), entered into a Joint Venture Agreement with PSI Gen 2 Funding, Inc. (“GEN2”), an Illinois corporation, to further development, marketing, licensing and/or sale of PSI technology and products. The joint venture is conducted through NEO Phototherapy, LLC, a recently formed Illinois limited liability company (“NEO”), with principal offices and records to be maintained at WCUI’s offices. See Non-Controlling Interests in Note 2 for more details.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (Loss) Per Share	Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the nine months ended June 30, 2019 and 2018, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At June 30, 2019 and 2018, the dilutive impact of outstanding stock options of 15,687,738 and 17,890,000 shares, respectively, and outstanding warrants for 66,832,049 and 69,022,753 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.
Revenue Recognition	Revenue Recognition In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for c We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”). Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements. We determine revenue recognition through the following steps: ● Identification of the contract, or contracts, with a customer ● Identification of the performance obligations in the contract ● Determination of the transaction price ● Allocation of the transaction price to the performance obligations in the contract ● Recognition of revenue when, or as, we satisfy a performance obligation. Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at September 30, 2018 was $8,624. No deferred revenue was recorded at June 30, 2019.
Non-Controlling Interests	Non-controlling Interests Through November 2018, non-controlling interest represented the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. On November 15, 2018, PSI and TMA entered into a Withdraw and Mutual Release Agreement to terminate their joint venture agreement. On the date of termination, the non-controlling interest’s share of the accumulated losses of the joint venture totaled to $405,383. Upon termination, during the three months ended December 31, 2018, the Company wrote-off the non-controlling interest’s share of the accumulated losses and recorded a loss from the deconsolidation of a non-controlling interest of $405,383. In December 2018, PSI entered into a Joint Venture Agreement with GEN2 to further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO. PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. Repayment of the $700,000 investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative net income/distributable cash in the amount of $300,000. Distributions thereafter will be made to PSI, GEN2 and other members in proportion to their respective Unit ownership, at the times and in the manner determined from time to time by the managers, in their sole discretion. GEN2 consists of accredited investors, and investment participation from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. As of June 30, 2019, GEN2 had received $700,000 of investments to contribute to NEO and the Company recorded its proportionate share of $476,000 to additional paid-in-capital and $224,000 to non-controlling interest. During the three and nine months ended June 30, 2019, NEO recorded a loss of $15,367 and $17,373, respectively, relating to its operations.
Stock-Based Compensation	Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Schedule of Company's Consolidated Subsidiaries	The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 100 % StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100 % Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015/November 15, 2018 50 % NEO Phototherapy LLC (“NEO”) The State of Illinois December 2018 50.5 %

Convertible Note Agreements (Ta

Convertible Note Agreements (Tables)	9 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	June 30, 2018 September 30, 2018 Convertible note payable (a) $ - $ 165,000 Convertible note payable (b) - 110,000 Debt discount – unamortized balance - (72,078 ) Convertible note payable, net $ - $ 202,922 (a) On March 5, 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). The balance of the unamortized discount at September 30, 2018 was $3,837. During the nine months ended June 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the nine months ended June 30, 2019. During the nine months ended June 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company’s common stock. During the nine months ended June 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at June 30, 2019. No amounts were outstanding under the agreement as of June 30, 2019. (b) On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). As of September 30, 2018, the Company had amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. During the nine months ended June 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the three and nine months ended June 30, 2019. During the three and nine months ended June 30, 2019, the Company amortized $21,389 and $68,241 of debt discount, respectively, leaving no unamortized balance at June 30, 2019. On April 2, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company’s common stock. No amounts were outstanding under the agreement as of June 30, 2019.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of Assumptions Used for Options Granted	The assumptions used for the option granted during the nine months ended June 30, 2019 are as follows: Exercise price $ 0.04 - $ 0.06 Expected dividends - Expected volatility 126.8 - 137.4% Risk free interest rate 1.73 - 2.47 Expected life of options 2.5
Schedule of Stock Option Activity	The table below summarizes the Company’s stock option activities for the nine months ended June 30, 2019: Number of Exercise Price Range Weighted Average Fair Value at Balance, September 30, 2018 17,946,667 $ 0.10 - 2.00 $ 0.28 $ 3,244,755 Granted 187,500 0.04 - 0.06 0.05 8,684 Cancelled (646,429 ) 0.14 - 0.19 0.17 - Exercised - - - - Expired (1,800,000 ) 0.40 0.40 - Balance, June 30, 2019 15,687,738 $ 0.04 – 2.00 $ 0.27 $ 3,253,439 Vested and exercisable, June 30, 2019 11,946,667 $ 0.04 – 2.00 $ 0.31 $ 2,185,052 Unvested, June 30, 2019 3,741,071 $ 0.14 – 0.19 $ 0.14 $ 1,068,387
Schedule of Outstanding and Exercisable Options by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable options as of June 30, 2019: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.06 - 0.39 13,975,238 3.30 $ 0.15 10,234,167 3.13 $ 0.15 0.40 - 0.99 312,500 0.62 0.40 312,500 0.62 0.40 1.00 - 1.99 750,000 1.50 1.00 750,000 1.50 1.00 2.00 650,000 1.50 2.00 650,000 1.50 2.00 $ 0.06 - 2.00 15,687,738 3.06 $ 0.27 11,946,667 3.07 $ 0.31
Schedule of Warrant Activity	The table below summarizes the Company’s warrants activities for the nine months ended June 30, 2019: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Issuance Balance, September 30, 2018 67,907,728 $ 0.12 - 0.67 $ 0.17 $ 3,434,560 Granted 284,714 0.15 0.15 17,803 Cancelled - - - - Exercised - - - - Expired (1,360,393 ) 0.40 – 0.67 0.47 - Balance, June 30, 2019 66,832,049 $ 0.12 - 0.40 $ 0.17 $ 3,452,363 Vested and exercisable, June 30, 2019 66,832,049 $ 0.12 - 0.40 $ 0.17 $ 3,452,363
Schedule of Outstanding and Exercisable Warrants by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable warrants as of June 30, 2019: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 59,279,384 2.15 $ 0.15 59,279,384 2.15 $ 0.15 0.21 – 0.49 7,552,665 1.05 0.26 7,552,665 1.05 0.26 0.50 – 0.67 - - - - - - $ 0.12 – 0.67 66,832,049 2.03 $ 0.17 66,832,049 2.03 $ 0.17

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of Assets of Reportable Segments	The detailed segment information of the Company is as follows: Assets By Segment June 30, 2019 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 1,687 $ 47,916 $ - $ 49,603 Inventories - 55,000 - 55,000 Total current assets 1,687 102,916 - 104,603 Property and equipment, net - - 1,827 1,827 Other assets - 1,760 - 1,760 Total other assets - 1,760 1,827 3,587 TOTAL ASSETS $ 1,687 $ 104,676 $ 1,827 $ 108,190
Schedule of Operations of Reportable Segments	Operations by Segment For the Nine Months Ended June 30, 2019 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ - $ 19,508 $ 19,508 Consulting services - - 13,867 13,867 Total Sales - - 33,375 33,375 Cost of goods sold - - 20,025 20,025 Gross profit - - 13,350 13,350 Operating expenses 716,900 399,111 299,656 1,415,667 Loss from operations $ (716,900 ) $ (399,111 ) $ (286,306 ) $ (1,402,317 ) For the Nine Months Ended June 30, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 45,000 $ 51,500 $ 96,500 Consulting services - - 42,750 42,750 Total Sales - 45,000 94,250 139,250 Cost of goods sold - - 51,625 51,625 Gross profit - 45,000 42,625 87,625 Operating expenses 940,169 176,859 615,820 1,732,848 Loss from operations $ (940,169 ) $ (131,859 ) $ (573,195 ) $ (1,645,223 )

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Entity incorporation, state country name			Nevada
Net loss	$ (515,832)	$ (1,580,437)	$ (1,674,230)	$ (2,826,017)
Cash used in operations			(972,857)	(790,081)
Shareholders' deficit	(1,002,306)	$ (611,263)	(1,002,306)	$ (611,263)	$ (1,078,563)	$ (825,160)	$ (761,250)	$ (290,449)
Cash on hand	$ 49,603		49,603			$ 4,210
Proceeds from short-term loans, contributions of capital by a joint venture partner and the sale of common stock			$ 1,018,250

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Nov. 15, 2018	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018
Deferred revenue									$ 8,624
Non-controlling interest's share of accumulated losses of joint venture	$ 405,383
Loss from deconsolidation of non-controlling interest					$ 405,383		405,383
Contributed capital			$ 700,000
Repayment of investments			700,000
Distributable cash			$ 300,000		$ 300,000
Noncontrolling interest, description			Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO. PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. Until such shares are distributed, the Company controls 68% of the joint venture and GEN2 the remaining 32%. PSI and GEN2 will manage NEO's day-to-day operations. PSI will contribute PSI technology to NEO and GEN2 will contribute $700,000. Repayment of the $700,000 investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative net income/distributable cash in the amount of $300,000.
Additional paid-in capital		23,716,791		23,716,791			23,716,791		22,450,252
Non-controlling interest		$ 218,440		218,440			218,440		$ (401,624)
Operating loss				$ (401,160)		$ (782,835)	$ (1,402,317)	$ (1,645,223)
Employees and Consultants [Member]
Additional units reserved for issuance			13.50%
Psoria-Shield, Inc [Member]
Ownership percentage		50.50%		50.50%			50.50%
Gen 2 Funding, Inc [Member]
Ownership percentage		36.00%		36.00%			36.00%
Proceeds from investment		$ 700,000
Illinois Limited Liability Company [Member]
Additional paid-in capital		476,000		$ 476,000			$ 476,000
Non-controlling interest		$ 224,000		224,000			224,000
Operating loss				$ 15,367			$ 17,373
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share							15,687,738	17,890,000
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share							66,832,049	69,022,753

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)	9 Months Ended
	Jun. 30, 2019
State or other jurisdiction of incorporation or organization	Nevada
Psoria-Shield, Inc [Member]
Name of consolidated subsidiary or entity	Psoria-Shield Inc. ("PSI")
State or other jurisdiction of incorporation or organization	The State of Florida
Date of incorporation or formation	Jun. 17, 2009
Date of acquisition/disposition	Aug. 24, 2012
Attributable interest	100.00%
StealthCo, Inc. [Member]
Name of consolidated subsidiary or entity	StealthCo, Inc. ("StealthCo")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Mar. 18, 2014
Attributable interest	100.00%
Psoria Development Company LLC. [Member]
Name of consolidated subsidiary or entity	Psoria Development Company LLC. ("PDC")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Jan. 15, 2015
Date of acquisition/disposition	Nov. 15, 2018
Attributable interest	50.00%
NEO Phototherapy LLC [Member]
Name of consolidated subsidiary or entity	NEO Phototherapy LLC ("NEO")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Dec. 31, 2018
Attributable interest	50.50%

Loans Payable from Officers a_2

Loans Payable from Officers and Shareholders (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018
Loans payable from officers and shareholders	$ 374,250		$ 66,000
Proceeds from short term debt	333,250	$ 427,500
Repayments of short term debt	25,000	$ 20,500
Unsecured Loans [Member] | Officers and Shareholders [Member]
Loans payable from officers and shareholders	374,250		$ 66,000
Proceeds from short term debt	333,250
Repayments of short term debt	$ 25,000
Debt instrument, interest rate, stated percentage	8.00%
Debt instrument, payment terms	Due one year from the date of issuance

Convertible Note Agreements - S

Convertible Note Agreements - Schedule of Convertible Notes Payable (Details) - USD ($)		Jun. 30, 2019	Sep. 30, 2018
Debt discount - unamortized balance			$ (72,078)
Convertible note payable, net			202,922
Convertible Note Payable One [Member]
Convertible note payable	[1]		165,000
Convertible Note Payable Two [Member]
Convertible note payable	[2]	$ 110,000	$ 110,000
[1]	On March 5, 2018, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.10 per share. The note matured in October 2018. The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company's calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). The balance of the unamortized discount at September 30, 2018 was $3,837. During the nine months ended June 30, 2019, the Company amended the terms of the agreement by extending the maturity date to January 2019 and reducing the conversion price from $0.10 per share to $0.07 per share. The reduction of the conversion price caused the Company to issue an additional 744,732 shares, which on the dates of amendment had a combined total fair value of $51,434, which was recorded a financing cost during the nine months ended June 30, 2019. During the nine months ended June 30, 2019, the individual converted $165,000 of the convertible note payable and $8,783 of accrued interest into 2,482,441 shares of the Company's common stock. During the nine months ended June 30, 2019, the Company amortized the remaining $3,837 of debt discount, leaving no unamortized balance at June 30, 2019. No amounts were outstanding under the agreement as of June 30, 2019.
[2]	On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.15 per share. The note matures in February 2019, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days' prior written notice. The note was past due as of March 31, 2019, but on April 2, 2019, was converted into shares of the Company's common stock (see below). The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company's calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). As of September 30, 2018, the Company had amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. During the nine months ended June 30, 2019, the Company amended the terms of the agreement by reducing the conversion price from $0.15 per share to $0.05 per share. The reduction of the conversion price caused the Company to issue an additional 1,551,854 shares, which on the date of amendment had a fair value of $108,630, which was recorded a financing cost during the three and nine months ended June 30, 2019. During the three and nine months ended June 30, 2019, the Company amortized $21,389 and $68,241 of debt discount, respectively, leaving no unamortized balance at June 30, 2019. On April 2, 2019, the individual converted the note payable of $110,000 and $6,389 of accrued interest into 2,327,781 shares of the Company's common stock. No amounts were outstanding under the agreement as of June 30, 2019.

Convertible Note Agreements -_2

Convertible Note Agreements - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Apr. 02, 2019	Sep. 30, 2018	Jul. 11, 2018	Mar. 05, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Proceeds from convertible notes payable								$ 150,000
Number of warrants issued to purchase shares					284,714		284,714
Warrant term					5 years		5 years
Warrant exercise price					$ 0.15		$ 0.15
Debt instrument, unamortized discount		$ 72,078
Amortization of debt discount						$ 69,837	$ 72,078	$ 205,674
Reducing conversion price per shares					$ 0.05		$ 0.05
Financing cost					$ 108,630		$ 108,630
Conversion of debt into common stock	$ 110,000
Accrued interest	$ 6,389
Conversion of debt into common stock, shares	2,327,781
Convertible Note Payable Agreement One [Member]
Debt instrument, unamortized discount		3,837
Reducing conversion price per shares					$ 0.07		$ 0.07
Financing cost					$ 51,434		$ 51,434
Convertible Note Payable Agreement One [Member] | Individual [Member]
Debt instrument, face amount				$ 165,000
Lender fee				15,000
Proceeds from convertible notes payable				$ 150,000
Number of restricted shares issued				300,000
Restricted shares of common stock at fair value				$ 48,000
Number of warrants issued to purchase shares				660,000
Warrant term				5 years
Warrant exercise price				$ 0.20
Debt instrument, collateral				unsecured
Debt instrument, convertible, terms of conversion feature				The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.10 per share.
Debt instrument conversion price				$ 0.10
Debt instrument maturity date description				October 2018			January 2019
Fair value of warrants				$ 55,032
Debt instrument, unamortized discount				$ 94,968
Amortization of debt discount							$ 3,837
Additional number of shares issued for conversion debt							744,732
Conversion of debt into common stock							$ 165,000
Accrued interest							$ 8,783
Conversion of debt into common stock, shares							2,482,441
Convertible Note Payable Agreement Two [Member] | Individual [Member]
Debt instrument, face amount			$ 110,000
Lender fee			10,000
Proceeds from convertible notes payable			$ 100,000
Number of restricted shares issued			200,000
Restricted shares of common stock at fair value			$ 36,000
Number of warrants issued to purchase shares			440,000
Warrant term			5 years
Warrant exercise price			$ 0.18
Debt instrument, collateral			unsecured
Debt instrument, convertible, terms of conversion feature			The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.15 per share.
Debt instrument conversion price			$ 0.15
Debt instrument maturity date description			February 2019
Fair value of warrants			$ 66,440
Debt instrument, unamortized discount		68,241	$ 33,560
Amortization of debt discount		$ 41,759			$ 21,389		$ 68,241
Additional number of shares issued for conversion debt							1,551,854

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018	Jan. 02, 2018	Jun. 30, 2010
Common stock issued for cash		$ 50,000	$ 10,000	$ 50,000
Common stock issued for cash, shares			142,857
Number of warrants issued to purchase common shares	284,714		284,714
Warrant term	5 years		5 years
Warrant exercise price	$ 0.15		$ 0.15
Number of stock issued for service			1,277,143
Number of stock issued for service, amount	$ 69,429	$ 84,600	$ 79,029	$ 111,300
Common stock, shares authorized	185,000,000		185,000,000		185,000,000
Number options to purchase of common stock			187,500
Options exercisable term			3 years 26 days
Stock based compensation			$ 235,819
Unvested compensation	$ 452,659		$ 452,659
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized						30,000,000	7,500,000
Stock Option [Member] | 2010 Non-Qualified Stock Option Plan [Member]
Shares of stock options remaining available for issuance	14,312,262		14,312,262
Warrant [Member]
Number of warrants issued to purchase common shares	284,714		284,714
Warrant term	5 years		5 years
Warrant exercise price	$ 0.15		$ 0.15
Options exercisable term			2 years 11 days
Aggregate intrinsic value for warrant shares outstanding
Employee [Member]
Number options to purchase of common stock			187,500
Fair value of stock options			$ 8,684
Options exercisable term			5 years
Employee [Member] | Minimum [Member]
Stock option exercise price per share	$ 0.04		$ 0.04
Employee [Member] | Maximum [Member]
Stock option exercise price per share	$ 0.06		$ 0.06

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Assumptions Used for Options Granted (Details)	9 Months Ended
	Jun. 30, 2019$ / shares
Expected dividends	0.00%
Expected life of options	2 years 6 months
Minimum [Member]
Exercise price	$ 0.04
Expected volatility	126.80%
Risk free interest rate	1.73%
Maximum [Member]
Exercise price	$ 0.06
Expected volatility	137.40%
Risk free interest rate	2.47%

Shareholders' Equity - Schedu_2

Shareholders' Equity - Schedule of Stock Option Activity (Details)	9 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Number of Option Shares Outstanding, Number, Beginning Balance | shares	17,946,667
Number of Option Shares Outstanding, Granted | shares	187,500
Number of Option Shares Outstanding, Cancelled | shares	(646,429)
Number of Option Shares Outstanding, Exercised | shares
Number of Option Shares Outstanding, Expired | shares	(1,800,000)
Number of Option Shares Outstanding, Number, Ending Balance | shares	15,687,738
Number of Option Shares Outstanding, Vested and exercisable, Ending Balance | shares	11,946,667
Number of Option Shares Outstanding, Unvested, Ending Balance | shares	3,741,071
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.28
Weighted Average Exercise Price, Granted	0.05
Weighted Average Exercise Price, Cancelled	0.17
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.40
Weighted Average Exercise Price, Number, Ending Balance	0.27
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.31
Weighted Average Exercise Price, Unvested, Ending Balance	$ 0.14
Fair Value at Date of Grant, Number, Beginning Balance | $	$ 3,244,755
Fair Value at Date of Grant, Granted | $	8,684
Fair Value at Date of Grant, Cancelled | $
Fair Value at Date of Grant, Exercised | $
Fair Value at Date of Grant, Expired | $
Fair Value at Date of Grant, Number, Ending Balance | $	3,253,439
Fair Value at Date of Grant, Vested and exercisable, Ending Balance | $	2,185,052
Fair Value at Date of Grant, Unvested, Ending Balance | $	$ 1,068,387
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.10
Weighted Average Exercise Price, Granted	0.04
Weighted Average Exercise Price, Cancelled	0.14
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.04
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.04
Weighted Average Exercise Price, Unvested, Ending Balance	0.14
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	2
Weighted Average Exercise Price, Granted	0.06
Weighted Average Exercise Price, Cancelled	0.19
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.40
Weighted Average Exercise Price, Number, Ending Balance	2
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	2
Weighted Average Exercise Price, Unvested, Ending Balance	$ 0.19

Shareholders' Equity - Schedu_3

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2018
Range of Exercise Prices, Lower Limit	$ 0.06
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	15,687,738	17,946,667
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 22 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.27	$ 0.28
Number of Options, Exercisable, Number	11,946,667
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 26 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.31
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.06
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Options, Outstanding, Number	13,975,238
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 3 months 19 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Options, Exercisable, Number	10,234,167
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 1 month 16 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Options, Outstanding, Number	312,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	7 months 13 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Options, Exercisable, Number	312,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	7 months 13 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.40
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	$ 1.99
Number of Options, Outstanding, Number	750,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 1
Number of Options, Exercisable, Number	750,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 1
Exercise Price Range Four [Member]
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	650,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 2
Number of Options, Exercisable, Number	650,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 2

Shareholders' Equity - Schedu_4

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member]	9 Months Ended
	Jun. 30, 2019USD ($)$ / sharesshares
Number of Warrant Shares Outstanding, Number, Beginning Balance | shares	67,907,728
Number of Warrant Shares Outstanding, Granted | shares	284,714
Number of Warrant Shares Outstanding, Cancelled | shares
Number of Warrant Shares Outstanding, Exercised | shares
Number of Warrant Shares Outstanding, Expired | shares	(1,360,393)
Number of Warrant Shares Outstanding, Number, Ending Balance | shares	66,832,049
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance | shares	66,832,049
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.17
Weighted Average Exercise Price, Granted	0.15
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.47
Weighted Average Exercise Price, Number, Ending Balance	0.17
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.17
Fair Value at Date of Issuance, Beginning Balance | $	$ 3,434,560
Fair Value at Date of Issuance, Granted | $	17,803
Fair Value at Date of Issuance, Cancelled | $
Fair Value at Date of Issuance, Exercised | $
Fair Value at Date of Issuance, Expired | $
Fair Value at Date of Issuance, Number, Ending Balance | $	3,452,363
Fair Value at Date of Issuance, Vested and exercisable, Ending Balance | $	$ 3,452,363
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.12
Weighted Average Exercise Price, Expired	0.40
Weighted Average Exercise Price, Number, Ending Balance	0.12
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.12
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.67
Weighted Average Exercise Price, Granted	0.15
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	0.67
Weighted Average Exercise Price, Number, Ending Balance	0.40
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.40

Shareholders' Equity - Schedu_5

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - $ / shares	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2018
Range of Exercise Prices, Lower Limit	$ 0.06
Range of Exercise Prices, Upper Limit	$ 2
Number of Warrants, Outstanding, Number	15,687,738	17,946,667
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	3 years 22 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.27	$ 0.28
Number of Warrants, Exercisable, Number	11,946,667
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	3 years 26 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.31
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.06
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Warrants, Outstanding, Number	13,975,238
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	3 years 3 months 19 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	10,234,167
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	3 years 1 month 16 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Warrants, Outstanding, Number	312,500
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	7 months 13 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Warrants, Exercisable, Number	312,500
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	7 months 13 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.40
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	$ 1.99
Number of Warrants, Outstanding, Number	750,000
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 1
Number of Warrants, Exercisable, Number	750,000
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 6 months
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 1
Warrant [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.67
Number of Warrants, Outstanding, Number	66,832,049
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 11 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.17
Number of Warrants, Exercisable, Number	66,832,049
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 11 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.17
Warrant [Member] | Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	59,279,384
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 1 month 24 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	59,279,384
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 1 month 24 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Warrant [Member] | Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.49
Number of Warrants, Outstanding, Number	7,552,665
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 18 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.26
Number of Warrants, Exercisable, Number	7,552,665
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 18 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.26
Warrant [Member] | Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	0.50
Range of Exercise Prices, Upper Limit	$ 0.67
Number of Warrants, Outstanding, Number
Number of Warrants, Outstanding, Weighted Average Exercise Price
Number of Warrants, Exercisable, Number
Number of Warrants, Exercisable, Weighted Average Exercise Price

Segment Reporting - Schedule of

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Cash	$ 49,603	$ 4,210
Inventories	55,000
Total current assets	104,603	5,760
Property and equipment, net	1,827	2,619
Other assets	1,760	16,760
Total other assets	3,587	19,379
TOTAL ASSETS	108,190	$ 25,139
Corporate [Member]
Cash	1,687
Inventories
Total current assets	1,687
Property and equipment, net
Other assets
Total other assets
TOTAL ASSETS	1,687
Medical Devices [Member]
Cash	47,916
Inventories	55,000
Total current assets	102,916
Property and equipment, net
Other assets	1,760
Total other assets	1,760
TOTAL ASSETS	104,676
Authentication and Encryption [Member]
Cash
Inventories
Total current assets
Property and equipment, net	1,827
Other assets
Total other assets	1,827
TOTAL ASSETS	$ 1,827

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Total Sales	$ 7,625	$ 71,500	$ 33,375	$ 139,250
Cost of goods sold	4,575	16,967	20,025	51,625
Gross profit	3,050	54,533	13,350	87,625
Operating expenses	404,210	837,368	1,415,667	1,732,848
Loss from operations	(401,160)	(782,835)	(1,402,317)	(1,645,223)
Trade [Member]
Total Sales	3,108	60,500	19,508	96,500
Consulting Services [Member]
Total Sales	$ 4,517	$ 11,000	13,867	42,750
Corporate [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses			716,900	940,169
Loss from operations			(716,900)	(940,169)
Corporate [Member] | Trade [Member]
Total Sales
Corporate [Member] | Consulting Services [Member]
Total Sales
Medical Devices [Member]
Total Sales				45,000
Cost of goods sold
Gross profit				45,000
Operating expenses			399,111	176,859
Loss from operations			(399,111)	(131,859)
Medical Devices [Member] | Trade [Member]
Total Sales				45,000
Medical Devices [Member] | Consulting Services [Member]
Total Sales
Authentication and Encryption [Member]
Total Sales			33,375	94,250
Cost of goods sold			20,025	51,625
Gross profit			13,350	42,625
Operating expenses			299,656	615,820
Loss from operations			(286,306)	(573,195)
Authentication and Encryption [Member] | Trade [Member]
Total Sales			19,508	51,500
Authentication and Encryption [Member] | Consulting Services [Member]
Total Sales			$ 13,867	$ 42,750

Legal Matters (Details Narrativ

Legal Matters (Details Narrative)	9 Months Ended
	Jun. 30, 2019USD ($)
Payment to negotiated settlement	$ 80,454
Interest rate of negotiated settlement	4.00%
CEO [Member] | Minimum [Member]
Trading expense	$ 130,000

Commitments (Details Narrative)

Commitments (Details Narrative)	9 Months Ended
	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Lease expiration date	Feb. 28, 2024
Monthly lease payment	$ 11,000
Total aggregate payment	640,000
Security deposit relating to the lease	$ 15,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2021	Sep. 03, 2019	Jun. 30, 2018	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018
Loans payable from officers and shareholders					$ 374,250		$ 66,000
Total authorized capital stock					185,000,000		185,000,000
Common stock new issues					142,857
Common stock new issue value			$ 50,000		$ 10,000	$ 50,000
Share Exchange Agreement [Member] | DTI Holdings Inc [Member] | Forecast [Member]
Common stock new issues	3,112,000
Common stock value per share	$ 4.50
Common stock new issue value	$ 14,004,000
Agreement description		On September 3, 2019, our Board of Directors unanimously approved, subject to stockholder approval: (1) execution and delivery of a proposed Share Exchange Agreement with DTI Holdings, Inc. ("DTI") relating to the share exchange and transfer of certain assets of SCI pursuant to the terms and conditions of a Memorandum of Agreement in substantially the form of the copy presented to the Board ("Agreement"); and (2) the amendment of our Articles of Incorporation to increase our total authorized capital stock from 185,000,000 common shares to 200,000,000 common shares ("Amendment"). As of September 18, 2019, holders of a majority of the outstanding shares of voting capital stock have executed written stockholder consents approving these actions. The Agreement provides, among other things, that: (1) DTI will pay the Company $500,000 upon the execution of a definitive share exchange agreement ("Share Exchange Agreement") which the parties will endeavor to negotiate and execute as quickly as possible, and not later than October 15, 2019; (2) DTI will pay the Company an additional $500,000 within seven days following the completion date of the transfer of all assets and/or full ownership of SCI to DTI, with such date to occur within 120 days following execution of the Share Exchange Agreement; (3) DTI will issue to the Company 3,112,000 shares of DTI common stock and will guaranty that the value of the 3,112,000 shares of DTI common stock will have a value of at least $4.50 per share ($14,004,000, in the aggregate), as of December 31, 2021; (4) To the extent that the value of the DTI common shares, as of December 31, 2021, is less than $4.50 per share ($14,004,000, in the aggregate), DTI will issue additional shares of DTI common stock, at the then current fair market value, in an amount sufficient to cause the resulting aggregate value of all shares of DTI common stock issued to the Company to be $14,004,000, in the aggregate; (5) DTI will assign the assets transferred by SCI, including trademarks, intellectual properties, and patents, to its subsidiary, Femtobitz, Inc., a Delaware corporation, and will pay to the Company 1% of annual gross revenue arising from or relating to operation of Femtobitz, Inc.; and (6) Upon closing of the share exchange, the Company's Chairman will be appointed an advisory board member of DTI and a board member of Femtobitz, Inc.
Officers and Shareholders [Member] | Unsecured Loans [Member]
Loans payable from officers and shareholders					$ 374,250		$ 66,000
Debt instrument, interest rate, stated percentage					8.00%
Debt instrument, payment terms					Due one year from the date of issuance
Subsequent Event [Member] | Share Exchange Agreement [Member] | Femtobitz, Inc. [Member]
Annual gross revenue				1.00%
Subsequent Event [Member] | Share Exchange Agreement [Member] | DTI Holdings Inc [Member]
Due from related party				$ 500,000
Due from related party in addition				$ 500,000
Subsequent Event [Member] | Share Exchange Agreement [Member] | DTI Holdings Inc [Member] | Minimum [Member]
Total authorized capital stock		185,000,000
Subsequent Event [Member] | Share Exchange Agreement [Member] | DTI Holdings Inc [Member] | Maximum [Member]
Total authorized capital stock		200,000,000
Subsequent Event [Member] | Unsecured Loans [Member]
Debt instrument, interest rate, stated percentage				8.00%
Debt instrument, payment terms				Due one year from the date of issuance
Subsequent Event [Member] | Officers and Shareholders [Member]
Loans payable from officers and shareholders				$ 50,000